Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788409 · ClinicalTrials.gov registry record
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 2,234
- Enrollment target
NCT02788409 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 2,234 participants.
The verdict
NCT02788409 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 2,234 participants
- Enrollment target
Study Summary
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study. Furthermore this study aims to provide further information about the documentation of bone metastases in Medicare data and the extent of use of only oral androgen deprivation drugs among patients with Medicare Part D coverage, as well as to estimate overall survival of the study population.
Interventions
- OTHER Not applicable for study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,234 participants |
| Start Date | 2016-05-15 |
| Est. Completion | 2018-05-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02788409
The ClinicalTrials.gov registry entry for NCT02788409 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Not applicable for study is the first listed.
NCT02788409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02788409 about?
NCT02788409 is a clinical study titled "Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US". This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study. Furthermore this study aims to p...
What is the current status of trial NCT02788409?
This trial is currently completed. The enrollment target is 2,234 participants. The study started on 2016-05-15. Estimated completion is 2018-05-09.
What interventions are being tested in trial NCT02788409?
The interventions under investigation include: Not applicable for study (OTHER).
Who is sponsoring clinical trial NCT02788409?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.